Phase II study of hexamethylmelamine (NSC 13875).
D000477:Alkylating Agents / Q000009:adverse effects*; D000963:Antimetabolites / Q000009:adverse effects*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006402:Hematologic Diseases / Q000139:chemically induced*; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D000477:Alkylating Agents; D000963:Antimetabolites